Inhibition of poly(ADP‐ribose) polymerase prevents irinotecan‐induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma
Open Access
- 21 June 2006
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 20 (10), 1709-1711
- https://doi.org/10.1096/fj.06-5916fje
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant gliomaCancer, 2005
- Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour ActivityMedicinal Chemistry Reviews - Online, 2004
- Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid TumorsClinical Cancer Research, 2004
- Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361JNCI Journal of the National Cancer Institute, 2004
- Mechanisms of resistance to topoisomerase I-targeting drugsOncogene, 2003
- A Novel Methionine-Based Signaling Mechanism Regulating the Expression of Thymidylate SynthaseCancer Biology & Therapy, 2003
- Cellular effects of CPT‐11 on colon carcinoma cells: Dependence on p53 and hMLH1 statusInternational Journal of Cancer, 2002
- Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system siteBlood, 2002
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialThe Lancet, 2000
- Involvement of the Mismatch Repair System in Temozolomide-Induced ApoptosisMolecular Pharmacology, 1998